Reynand Wu
November 4, 2026
As the dust settles on the recent midterm elections, Washington is bracing for a tectonic shift in health policy. With the Democratic Party assuming control of Congress, the legislative agenda is poised to pivot away from the deregulatory themes of the previous administration toward a posture of oversight, investigative scrutiny, and targeted reform.
Analysts suggest that while the new majority faces significant structural headwinds—including a lack of a veto-proof Senate majority and an impending 2028 presidential cycle—the appetite for challenging the current administration’s health initiatives is immense. From the potential impeachment of high-level HHS officials to the tactical reversal of Medicaid funding cuts, the stage is set for a high-stakes clash between the legislative and executive branches.
The Legislative Agenda: Oversight and Accountability
The incoming Democratic leadership has signaled that their first priority is not necessarily sweeping new legislation, but rather a robust exercise of their investigative powers. Leading the list of grievances is the tenure of HHS Secretary Robert F. Kennedy Jr.
Bruce Mirken, communications co-chair at Defend Public Health, frames the new congressional mandate as a corrective measure. "We’re heartened to see a number of people elected who are likely to be public health champions," Mirken noted. He specifically highlighted the influx of medically trained lawmakers, including Senators-elect Abdul El-Sayed, MD, and Representatives-elect Richard Pan, MD, and Mitchell Berman, RN.
According to Mirken, the primary objective is to hold the executive branch accountable for what he terms "public health malpractice." "One of our top priorities is a complete and thorough investigation and airing of Secretary Kennedy’s record of malfeasance and disinformation," Mirken stated. "We believe this should lead to articles of impeachment. Congress needs to assert its authority and start the process of removing Mr. Kennedy."
Beyond individual removals, Democrats are eyeing the budget. They allege that the current administration manipulated funds appropriated by Congress, specifically regarding disease surveillance, food safety, and long-term health research. Expect the House and Senate to utilize the power of the purse to claw back control over HHS spending protocols.
A Cautious Outlook: The Reality of Divided Government
While the rhetoric in the capital is fiery, policy experts warn that the transition from campaign promises to substantive law will be fraught with difficulty. Tom Miller, a senior fellow at the American Enterprise Institute, urges a tempered view of the upcoming session.
"Tuesday’s sweeping election results will trigger the usual post-mandate cross pressures for congressional Democrats," Miller explained. "There is the urge to get some things done, but also a strong temptation for factions to overstate and overreach their mandate to settle scores and pursue boundary-stretching changes not supported by the voters."
Miller notes that the "calendar pressures" of the 2028 presidential campaign are already beginning to shorten the legislative window. With voters expressing a general, albeit vague, desire for lower prices and better access to care, Miller argues that defining a legislative consensus will be the greatest challenge for new leadership.
"Expect few large reforms or rollbacks of recent Trump administration policy changes," Miller added. "While some limited consensus may be available for technical adjustments to the No Surprises Act, or targeted rhetoric against hospitals, drugmakers, and insurers, the gap between political theater and reality will remain wide."
Targeted Reforms: Where Bipartisan Ground Might Exist
Despite the polarized atmosphere, experts believe there is room for movement on specific cost-containment measures. Thomas Campanella, professor emeritus of health economics at Baldwin Wallace University, identifies several areas where legislative action could potentially gain traction:
- Site-Neutral Hospital Payments: A long-standing debate, there is growing support for equalizing payments for the same services, regardless of whether they are provided in a hospital or a physician’s office.
- Anti-Trust Enforcement: Increased scrutiny regarding the vertical and horizontal integration of hospital systems remains a potential point of bipartisan convergence.
- 340B Program Reform: Addressing alleged abuses in the 340B drug pricing program is a perennial target for reformers looking to lower systemic costs.
- Transparency Mandates: Expect a push for stricter, user-friendly enforcement of price and quality transparency rules for both hospitals and insurers.
- Primary and Rural Care: There remains a strong, albeit quiet, bipartisan consensus regarding the need for enhanced investment in rural healthcare infrastructure.
The Medicaid Battleground: Reversals and Delays
Perhaps the most tangible impact of the new Congress will be felt within the Medicaid program. The "One Big Beautiful Bill," a reconciliation package passed last summer, included significant cuts to Medicaid and the Supplemental Nutrition Assistance Program (SNAP).
Edwin Park, a research professor at Georgetown University’s Center for Children and Families, believes that reversing or delaying these cuts will be a top-tier objective for Democrats. "The House and Senate will likely try to repeal the Medicaid and SNAP benefit cuts included in the reconciliation bill," Park said. "If that is not successful, they may attempt to delay some of those cuts to provide relief to states and beneficiaries."
Furthermore, the clock is ticking on critical funding provisions. Programs such as Disproportionate Share Hospital (DSH) payments, which provide a lifeline to safety-net facilities, are set to expire by the end of the year. Congress must act to avoid a funding cliff that could destabilize hospitals nationwide.
Scrutinizing CMS Implementation
Park also predicts a new level of congressional oversight regarding the Centers for Medicare & Medicaid Services (CMS). "There have been a number of occurrences where CMS has gone well beyond what the reconciliation bill requires," Park noted. He pointed specifically to interim final rules regarding work-reporting requirements and the financing of Medicaid waivers. According to Park, there is currently a "black box" regarding how drug prices are obtained and which drugs are subject to rebates, necessitating a push for greater administrative transparency.
Implications: The Limits of Legislative Power
The central question remains: Can a Democratic Congress force meaningful change when a Republican administration still holds the veto pen?
While most reforms face the steep climb of a non-veto-proof Senate, the political calculus is evolving. Mirken maintains that even symbolic victories are necessary to restore public faith. "It’s worth trying," he argued. "People need to see that this new Congress is attempting to fix the damage done over the last two years."
However, the reality of the 2026-2028 cycle suggests a period of "aspirational legislating." As Miller noted, the limited attention span of both voters and officeholders, combined with the onset of the next presidential cycle, means that the most significant outcomes may be found in investigative hearings, public reports, and the setting of the stage for the 2028 election, rather than in the passage of landmark, bipartisan health reform.
Chronology of Expected Challenges
- Late 2026: Immediate focus on expiring Medicaid funding (DSH payments) and initial hearings on HHS management.
- Early 2027: Attempted legislative maneuvers to delay or repeal reconciliation-based cuts to Medicaid/SNAP.
- Mid-2027: Heightened scrutiny of CMS rule-making and potential committee-led investigations into the HHS Secretary’s office.
- Late 2027 – 2028: Legislative gridlock as the presidential campaign cycle dominates the federal agenda.
Conclusion: A Shift in Tone
The transition to a Democratic-controlled Congress marks the end of a period of executive-led health policy and the beginning of a period of legislative resistance. While the ability to pass new, sweeping mandates is constrained, the capacity for the new Congress to disrupt the current administration’s trajectory—through oversight, budget restrictions, and public advocacy—is significant. For patients, providers, and stakeholders, the next two years will be defined by an intense focus on transparency, the reversal of budget cuts, and a deeply skeptical approach to federal health agencies.
Sagoh
Neng Nana
